CA209-73L
03 Dec 2020
CA209-73L
NCT04026412
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
Bristol-Myers Squibb
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | Non-small Cell Lung Cancer |
Cancer Stage | Locally Recurrent or Locally Advanced; Early/In situ |
Anticipated Start Date | 2019-08-20 |
Anticipated End Date | 2024-11-30 |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Dr Nimit Singhal |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs